CellVec
CellVec is a GMP-certified gene therapy Contract Development and Manufacturing Organisation (CDMO) specializing in custom viral vectors for pre-clinical and clinical applications. Their mission is to empower clients by designing and building vectors that facilitate the transformation of therapeutic ideas into clinical practice, focusing on innovation for patient benefit. They leverage a proprietary lentivirus-based platform to overcome technological bottlenecks in viral vector production, supporting the advancement of gene therapies from bench to bedside.
Industries
Nr. of Employees
small (1-50)
Products
GMP Clinical-Grade Retro and Lentiviral Vectors API
Clinical grade retro and lentiviral vectors manufactured under GMP as Active Pharmaceutical Ingredients for human gene therapy utilizing single-use, closed system technologies.
Manufacturing
Manufacture of clinical grade retro and lentiviral vector under GMP as Active Pharmaceutical Ingredients for human gene therapy.
GMP Manufacturing Facility
CellVec’s state-of-the-art GMP manufacturing facility, constructed based on international specifications, designed to accommodate flexible viral vector production runs for gene therapy and cellular ATMPs.
CellVec Vector Platform
A lentivirus-based platform designed to overcome technological bottlenecks in the upscale production of viral vectors and develop novel gene transfer technologies for advanced therapies.
Process Development
Bespoke process development services including transgene vector construct design, viral vector process development, and technology transfer.
Quality Control and Characterisation
In-house developed viral vector quantification assays and comprehensive quality characterisation via strategic external partnerships.
GMP Clinical-Grade Retro and Lentiviral Vectors API
Clinical grade retro and lentiviral vectors manufactured under GMP as Active Pharmaceutical Ingredients for human gene therapy utilizing single-use, closed system technologies.
Manufacturing
Manufacture of clinical grade retro and lentiviral vector under GMP as Active Pharmaceutical Ingredients for human gene therapy.
GMP Manufacturing Facility
CellVec’s state-of-the-art GMP manufacturing facility, constructed based on international specifications, designed to accommodate flexible viral vector production runs for gene therapy and cellular ATMPs.
CellVec Vector Platform
A lentivirus-based platform designed to overcome technological bottlenecks in the upscale production of viral vectors and develop novel gene transfer technologies for advanced therapies.
Process Development
Bespoke process development services including transgene vector construct design, viral vector process development, and technology transfer.
Quality Control and Characterisation
In-house developed viral vector quantification assays and comprehensive quality characterisation via strategic external partnerships.
Services
Design and optimisation of transgene constructs and manufacturing processes, including transfection ratio optimisation, media reformulation, critical process parameter identification and technology transfer for customised processes.
GMP manufacture of clinical-grade retroviral and lentiviral vectors including upstream processing, downstream purification and aseptic fill–finish into cryobags or vials using single-use closed systems.
Regulatory support and quality assurance services operating within a GMP-certified pharmaceutical quality system aligned to PIC/S and other major regulatory frameworks, including support for audits.
In-house viral vector quantification (flow cytometry) and qPCR-based genome-integrated vector copy number assays, plus coordinated external testing for bioburden, mycoplasma, endotoxin, adventitious agents and residual impurities.
End-to-end project management from client onboarding through product release and delivery, coordinating timelines and expectations across development and manufacturing activities.
Design and optimisation of transgene constructs and manufacturing processes, including transfection ratio optimisation, media reformulation, critical process parameter identification and technology transfer for customised processes.
GMP manufacture of clinical-grade retroviral and lentiviral vectors including upstream processing, downstream purification and aseptic fill–finish into cryobags or vials using single-use closed systems.
Regulatory support and quality assurance services operating within a GMP-certified pharmaceutical quality system aligned to PIC/S and other major regulatory frameworks, including support for audits.
In-house viral vector quantification (flow cytometry) and qPCR-based genome-integrated vector copy number assays, plus coordinated external testing for bioburden, mycoplasma, endotoxin, adventitious agents and residual impurities.
End-to-end project management from client onboarding through product release and delivery, coordinating timelines and expectations across development and manufacturing activities.
Expertise Areas
- Viral vector manufacturing (lentiviral and retroviral)
- GMP biologics manufacturing and quality systems
- Process development for viral vectors
- Cell bank and producer cell line development
Key Technologies
- Lentiviral vector design (self-inactivating)
- GMP-compatible plasmid expression systems
- HEK293T-derived master cell banks
- Single-use closed bioprocess systems